Not yet recruiting
Addition of ritonavir to ibrutinib treatment in patients with chronic leukemia and certain types of lymphoma
2026-526101-15-00· Phase 2· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Source
Recruiting
A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025).
NCT07722611· Phase 2/3· Merck Sharp & Dohme LLC· Source
Not yet recruiting
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
NCT07861100· Phase 3· Novo Nordisk A/S· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
NCT07541170· Phase 3· Hoffmann-La Roche· Source
Recruiting
HO182 CLL: Treatment of patients with chronic lymphocytic leukemia (CLL) with 6 cycles of rituximab in combination with 6 or 26 cycles of venetoclax upon recurrence of the disease after previous treatment
2025-524283-38-00· Phase 3· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Source
Recruiting
ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3
NCT06716021· Phase 3· Milestone Pharmaceuticals Inc.· Source
Not yet recruiting
HOVON 168:Study on epcoritamab in frail patients with diffuse large B-Cell lymphoma (DLBCL) who have not been treated before
2025-524230-25-00· Phase 2· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Source
Recruiting
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001· Phase 3· Novo Nordisk A/S· Source
Recruiting
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
2025-521546-23-00· Phase 3· Novartis Pharma AG· Source
Not yet recruiting
Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy
NCT07486687· Phase 3· The Netherlands Cancer Institute· Source
Recruiting
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
NCT07361510· Phase 3· Bristol-Myers Squibb· Source
Recruiting
Neoadjuvant FOLFOXIRI and Chemoradiotherapy versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy, followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer
NCT07472868· Phase 3· Catharina Ziekenhuis Stichting· Source
Recruiting
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
NCT07223814· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source
Recruiting
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
NCT07253285· Phase 3· Novo Nordisk A/S· Source
Recruiting
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390· Phase 3· Eli Lilly and Company· Source
Recruiting
ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer
NCT07188025· Phase 3· Erasmus Medical Center· Source
Recruiting
Preventing postoperative complications in patients undergoing high-risk pancreatoduodenectomy with a bundle approach including hydrocortisone, ocreotide, and teres ligament patch (PANENCA): an international randomized controlled multicenter trial
2024-519667-18-00· Phase 4· Amsterdam UMC Stichting· Source
Recruiting
A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy.
2024-512753-24-00· Phase 3· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Source
Recruiting
Continuing ovulation induction with letrozole versus switching to gonadotropins in women with polycystic ovary syndrome (MOVIN-II study)
2024-519354-36-00· Phase 4· Amsterdam UMC Stichting· Source
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· Phase 3· Boehringer Ingelheim· Source
Recruiting
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)
2023-510294-34-00· Phase 3· University Of Cologne· Source
Recruiting
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
NCT06652438· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source
Recruiting
StAtins in Frail oldEr patients with ischemic Stroke or Transient ischemic attack – The Randomized Controlled Trial
2024-517343-31-00· Phase 4· Amsterdam UMC Stichting· Source
Recruiting
A Study to Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced Coagulopathy
NCT06854640· Phase 1· Bayer· Source
Active, not recruiting
Multi-institutional Evaluation of the Cost-effectiveness of PSMA-PET/CT for the Detection of Pelvic Lymph Node Invasion in Newly Diagnosed Prostate Cancer Patients (PSMA-SELECT).
2024-518171-59-00· Phase 4· Canisius Wilhelmina Ziekenhuis· Source
Recruiting
A multi-centred, partially randomised, patient-preference trial of radical surgery versus adjuvant chemoradiotherapy after local excision for early rectal cancer.
NCT02371304· Phase 3· Amsterdam UMC Stichting· Source
Recruiting
Beta-Lactam Antibiotics InitiaL ExpoSure OptimisEd in CriticallY Ill Patients with SEpsis
NCT06766461· Phase 4· Erasmus Medical Center· Source
Recruiting
Stopping or continuing blood thinners after stroke at young age without a known cause: STOP trial
2024-513092-40-00· Phase 4· Stichting Radboud universitair medisch centrum· Source
Recruiting
Ulipristal versus surgery for symptomatic uterine fibroids
2024-512602-26-00· Phase 4· Amsterdam UMC Stichting· Source
Recruiting
DAROTAXEL
2024-516939-28-00· Phase 2· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Source
Recruiting
Timing of start of systemlc treatment for asymptomatic MEtastasized PANcreatic cancer (TIMEPAN): a prospective multicenter patient preference cohort
NCT04897854· Phase 3· Amsterdam UMC· Source
Recruiting
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
NCT06623422· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
NCT05947955· Phase 2· BioAegis Therapeutics Inc.· Source
Active, not recruiting
Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis (NEXT-MS)
NCT04225312· Phase 4· Amsterdam UMC Stichting· Source
Recruiting
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288· Phase 3· Boehringer Ingelheim· Source
Active, not recruiting
Noisy Rebels; Non-inferiority study of rituximab compared to ocrelizumab in relapsing MS
2022-502664-21-00· Phase 4· Amsterdam UMC· Source
Recruiting
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT04928846· Phase 3· AbbVie· Source
Active, not recruiting
Personalized dosing of ocrelizumab in MS
2024-513193-22-00· Phase 4· Amsterdam UMC Stichting· Source
Active, not recruiting
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
NCT04927780· Phase 3· Erasmus Medical Center· Source
Recruiting
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
NCT04774159· Phase 3· Population Health Research Institute· Source
Active, not recruiting
Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer
NCT01898117· Phase 2· The Netherlands Cancer Institute· Source